AP NEWS

Global Nuclear Medicine Market: Overview & Outlook (2017-2026) - ResearchAndMarkets.com

November 15, 2018

DUBLIN--(BUSINESS WIRE)--Nov 15, 2018--The “Nuclear Medicine - Global Market Outlook (2017-2026)” report has been added to ResearchAndMarkets.com’s offering.

According to this report, the Global Nuclear Medicine is accounted for $3.5 billion in 2017 and is expected to reach $6.5 billion by 2026 growing at a CAGR of 7.1% during the forecast period.

Factors such as growing demand for early & precise diagnostic methods, increasing incidence of cancer and cardiovascular disorders and huge demand for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are driving the market growth.

However, supply deficiency, reimbursement hurdles for the manufacturer and high capital investment are restricting the growth of the growth.

Moreover, rising economies, upcoming radioisotopes and increasing usage across neurological applications are providing ample opportunities for the market growth.

On the basis of application, therapeutic segment witnessed steady growth due to the introduction of advanced protective measures and growing awareness regarding the therapeutic procedures.

By geography, North America is dominating the market during the forecasting period owing to increasing aging population, technological advancements and the presence of favorable reimbursement policies in this region.

Key Topics Covered

1 Executive Summary

2 Preface

2.1 Abstract

2.2 Stake Holders

2.3 Research Scope

2.4 Research Methodology

2.4.1 Data Mining

2.4.2 Data Analysis

2.4.3 Data Validation

2.4.4 Research Approach

2.5 Research Sources

2.5.1 Primary Research Sources

2.5.2 Secondary Research Sources

2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Product Analysis

3.7 Application Analysis

3.8 End User Analysis

3.9 Emerging Markets

3.10 Futuristic Market Scenario

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Nuclear Medicine Market, By Product

5.1 Introduction

5.2 Therapeutic

5.2.1 Brachytherapy

5.2.1.1 Iodine-125

5.2.1.2 Iridium-192

5.2.1.3 Cesium-131

5.2.1.4 Palladium-103

5.2.1.5 Other Brachytherapies

5.2.2 Beta emitters

5.2.2.1 Lu-117

5.2.2.2 Iodine-131

5.2.2.3 Samarium-153

5.2.2.4 Yttrium-90

5.2.2.5 Rhenium 186/188

5.2.2.6 Strontium 89

5.2.2.7 Other beta emitters

5.2.3 Alpha emitters

5.2.3.1 RA-223

5.2.3.2 Other alpha emitters

5.3 Diagnostic

5.3.1 Positron Emission Tomography (PET)

5.3.1.1 RB-82

5.3.1.2 F-18

5.3.1.3 Other PET products

5.3.2 Single Photon Emission Computed Tomography (SPECT)

5.3.2.1 TL-201

5.3.2.2 TC-99m

5.3.2.3 GA-67

5.3.2.4 Other SPECT products

6 Global Nuclear Medicine Market, By Application

6.1 Introduction

6.2 Therapeutic

6.2.1 Endocrine Tumors

6.2.2 Lymphoma

6.2.3 Bone Metastasis

6.2.4 Thyroid

6.2.5 Other Therapeutic Applications

6.3 Diagnostic

6.3.1 Thyroid

6.3.2 Neurology

6.3.3 Lymphoma

6.3.4 Cardiology

6.3.5 Oncology

6.3.6 Other Diagnostics

7 Global Nuclear Medicine Market, By End User

7.1 Introduction

7.2 Research institutes

7.3 Hospitals and diagnostic centers

8 Global Nuclear Medicine Market, By Geography

8.1 Introduction

8.2 North America

8.2.1 US

8.2.2 Canada

8.2.3 Mexico

8.3 Europe

8.3.1 Germany

8.3.2 UK

8.3.3 Italy

8.3.4 France

8.3.5 Spain

8.3.6 Rest of Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 New Zealand

8.4.6 South Korea

8.4.7 Rest of Asia Pacific

8.5 South America

8.5.1 Argentina

8.5.2 Brazil

8.5.3 Chile

8.5.4 Rest of South America

8.6 Middle East & Africa

8.6.1 Saudi Arabia

8.6.2 UAE

8.6.3 Qatar

8.6.4 South Africa

8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures

9.2 Acquisitions & Mergers

9.3 New Product Launch

9.4 Expansions

9.5 Other Key Strategies

10 Company Profiling

10.1 Bayer AG

10.2 Medtronic, plc

10.3 General Electric Co.

10.4 Cardinal Health, Inc.

10.5 IBA Group

10.6 BWX Technologies

10.7 Australian Nuclear Science & Technology Organization (ANSTO)

10.8 Mallinckrodt plc.

10.9 Eckert & Ziegler Group

10.10 Lantheus Medical Imaging, Inc.

10.11 Jubilant Life Sciences

10.12 Eczacibasi-Monrol Nuclear Products

10.13 Curium

10.14 Bracco Imaging S.p.A

10.15 NTP Radioisotopes SOC Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/kk5wsv/global_nuclear?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181115005703/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Nuclear Medicine and Radiopharmacology

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/15/2018 11:34 AM/DISC: 11/15/2018 11:34 AM

http://www.businesswire.com/news/home/20181115005703/en

AP RADIO
Update hourly